Tempus AI Surges Since IPO as FDA Clearance Boosts Growth Outlook

Core Insights - Tempus AI, Inc. (NASDAQ:TEM) is recognized as one of the 11 best-performing IPOs in the last two years, with a significant stock price target increase following strong financial results and FDA approval for its product [1][3]. Financial Performance - In Q2 2025, Tempus AI reported revenue of $314.6 million, marking an impressive increase of 89.6% year-over-year, primarily driven by a 115% rise in Genomics revenue due to strong oncology volume growth [2]. - The company has achieved a notable growth of 111.50% since its IPO, reflecting a positive market outlook [3]. Regulatory Developments - On September 11, 2025, Tempus AI announced it received 510(k) clearance from the FDA for its updated Tempus Pixel, an AI-powered cardiac imaging platform, enhancing its capabilities for cardiac MR image analysis [2]. Company Background - Founded in 2015 and headquartered in Illinois, Tempus AI operates within the healthcare technology sector, focusing on applying artificial intelligence to clinical and molecular data to advance precision medicine [4].